

# Osteoarthritis and Cartilage



## The OA Trial Bank: meta-analysis of individual patient data from knee and hip osteoarthritis trials show that patients with severe pain exhibit greater benefit from intra-articular glucocorticoids



M. van Middelkoop <sup>†</sup>\*, N.K. Arden <sup>‡§||</sup>, I. Atchia <sup>¶</sup>, F. Birrell <sup>¶</sup>, J. Chao <sup>#</sup>, M.U. Rezende <sup>††</sup>, R.G.W. Lambert <sup>††</sup>, P. Ravaud <sup>§§</sup>, J.W. Bijlsma <sup>||||</sup>, M. Doherty <sup>¶¶</sup>, K.S. Dziedzic <sup>##</sup>, L.S. Lohmander <sup>†††</sup> <sup>†††</sup>, T.E. McAlindon <sup>§§§</sup>, W. Zhang <sup>¶¶</sup>, S.M.A. Bierma-Zeinstra <sup>†</sup>

<sup>†</sup> Erasmus MC Medical University Center Rotterdam, Department of General Practice, The Netherlands

<sup>‡</sup> Oxford NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, OX3 7LD, UK

<sup>§</sup> Arthritis Research UK Centre of Excellence for Sports, Exercise and Osteoarthritis, University of Oxford, OX3 7LD, UK

<sup>||</sup> MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton SO16 6YD, UK

<sup>¶</sup> Northumbria Healthcare NHS Foundation Trust, University of Newcastle, UK

<sup>#</sup> UCSD School of Medicine, La Jolla, CA, USA

<sup>††</sup> Instituto de Ortopedia e Traumatologia, Faculdade de Medicina, HCFMUSP, Sao Paulo, Brazil

<sup>††</sup> Department of Radiology & Diagnostic Imaging, University of Alberta, Edmonton, Canada

<sup>§§</sup> Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité, Paris, France

<sup>||||</sup> University Medical Center Utrecht, Department of Rheumatology & Clinical Immunology, Utrecht, The Netherlands

<sup>¶¶</sup> Division of Rheumatology, Orthopaedics and Dermatology, University of Nottingham, Nottingham, UK

<sup>##</sup> Arthritis Research UK Primary Care Centre, Primary Care Sciences, Keele University, UK

<sup>†††</sup> Lund University, Department of Orthopaedics, Clinical Sciences Lund, Sweden

<sup>†††</sup> Institute of Sports Science and Clinical Biomechanics, Department of Orthopaedics and Traumatology, University of Southern Denmark, Denmark

<sup>§§§</sup> Tufts University, Department of Medicine, Boston, USA

### ARTICLE INFO

#### Article history:

Received 9 July 2015

Accepted 22 January 2016

#### Keywords:

IPD analysis

Osteoarthritis

Knee

Hip

IA glucocorticoid

Injection

### SUMMARY

**Objective:** To evaluate the efficacy of intra-articular (IA) glucocorticoids for knee or hip osteoarthritis (OA) in specific subgroups of patients with severe pain and inflammatory signs using individual patient data (IPD) from existing trials.

**Design:** Randomized trials evaluating one or more IA glucocorticoid preparation in patients with knee or hip OA, published from 1995 up to June 2012 were selected from the literature. IPD obtained from original trials included patient and disease characteristics and outcomes measured. The primary outcome was pain severity at short-term follow-up (up to 4 weeks). The subgroup factors assessed included severe pain ( $\geq 70$  points, 0–100 scale) and signs of inflammation (dichotomized in present or not) at baseline. Multilevel regression analyses were applied to estimate the magnitude of the effects in the subgroups with the individuals nested within each study.

**Results:** Seven out of 43 published randomized clinical trials ( $n = 620$ ) were included. Patients with severe baseline pain had a significantly larger reduction in short-term pain, but not in mid- and long-term pain, compared to those with less severe pain at baseline (Mean Difference 13.91; 95% Confidence Interval 1.50–26.31) when receiving IA glucocorticoid injection compared to placebo. No statistical significant interaction effects were found between inflammatory signs and IA glucocorticoid injections compared to placebo and to tidal irrigation at all follow-up points.

\* Address correspondence and reprint requests to: M. van Middelkoop, Erasmus MC Medical University Rotterdam, Department of General Practice, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands. Tel: 31-10-7032114.

E-mail addresses: [m.vanmiddelloop@erasmusmc.nl](mailto:m.vanmiddelloop@erasmusmc.nl) (M. van Middelkoop), [nigel.arden@ndorms.ox.ac.uk](mailto:nigel.arden@ndorms.ox.ac.uk) (N.K. Arden), [Ismael.Atchia@northumbria-healthcare.nhs.uk](mailto:Ismael.Atchia@northumbria-healthcare.nhs.uk) (I. Atchia), [fraser.birrell@newcastle.ac.uk](mailto:fraser.birrell@newcastle.ac.uk) (F. Birrell), [jeannie.chao@gmail.com](mailto:jeannie.chao@gmail.com) (J. Chao), [murezende@uol.com.br](mailto:murezende@uol.com.br) (M.U. Rezende), [rlambert@ualberta.ca](mailto:rlambert@ualberta.ca) (R.G.W. Lambert), [philipperravaud@gmail.com](mailto:philipperravaud@gmail.com) (P. Ravaud), [J.W.J.Bijlsma@umcutrecht.nl](mailto:J.W.J.Bijlsma@umcutrecht.nl) (J.W. Bijlsma), [Michael.Doherty@nottingham.ac.uk](mailto:Michael.Doherty@nottingham.ac.uk) (M. Doherty), [k.s.dziedzic@keele.ac.uk](mailto:k.s.dziedzic@keele.ac.uk) (K.S. Dziedzic), [stefan.lohmander@med.lu.se](mailto:stefan.lohmander@med.lu.se) (L.S. Lohmander), [tmcalindon@tuftsmedicalcenter.org](mailto:tmcalindon@tuftsmedicalcenter.org) (T.E. McAlindon), [Weiya.Zhang@nottingham.ac.uk](mailto:Weiya.Zhang@nottingham.ac.uk) (W. Zhang), [s.bierma-zeinstra@erasmusmc.nl](mailto:s.bierma-zeinstra@erasmusmc.nl) (S.M.A. Bierma-Zeinstra).

**Conclusions:** This IPD meta-analysis demonstrates that patients with severe knee pain at baseline derive more benefit from IA glucocorticoid injection at short-term follow-up than those with less severe pain at baseline.

© 2016 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.

## Background

Given the small to moderate effect size of symptomatic treatments in osteoarthritis (OA) and the heterogeneity of OA patients, treatment guidelines for OA have addressed the need for research on clinical predictors of response to these different treatments<sup>1,2</sup>. However, the identification of responsive subgroups is challenging. In order to ensure that the right patients receive the right treatment, it is essential to use appropriate methodologies. Some trials have focussed on the different OA joint groups (e.g., hand, hip, knee or foot) and for treatment specifically aimed at certain OA subgroups such as osteotomy for varus knee OA<sup>3</sup>. However, to design trials on every available treatment for every identified subgroup would be expensive and unrealistic.

*Post hoc* analyses within individual trials are frequently applied to identify subgroups with different treatment responsiveness. However, such analyses are not powered *a priori* and therefore are subject to a high risk of type I and type II errors<sup>4,5</sup>. A methodologically robust method is to test for subgroup–treatment interaction effects<sup>3</sup>. This method carries a much smaller risk of false-positive results but requires large sample sizes to detect the interaction between subgroup variables and treatment. A meta-analysis for quantifying interaction effects using individual patient data (IPD) may help to overcome the power problem in individual trials<sup>6</sup>. In a meta-analysis using IPD, in which the data of several trials are pooled, the interaction effects between subgroups and treatment can be reliably assessed and potential confounders at both study and individual patient levels can be adjusted for<sup>6</sup>.

The OA Trial Bank initiative was therefore commenced in 2010 to collect and analyse IPD of published RCTs in OA<sup>7</sup>. The OA Trial Bank brings together data from individuals with OA recruited for published RCTs from different countries around the world to form a databank.

Intra-articular (IA) glucocorticoid injections are frequently applied in knee or hip OA patients who are unresponsive to non-invasive treatments or oral non-steroidal anti-inflammatory drugs (NSAIDs). An IA glucocorticosteroid injection is particularly recommended for OA patients with signs of local inflammation<sup>2,8–11</sup>. The Cochrane systematic review on the effectiveness of IA glucocorticoid injection in knee OA found some evidence for the efficacy of IA glucocorticoid injections compared to IA placebo for pain and patient global assessment at 1 week post-injection, with evidence also for continuing efficacy at 2 and 3 weeks post-injection<sup>10</sup>. It is however suggested that especially patients with clinical evidence of inflammation would benefit more from IA glucocorticoid injections<sup>12</sup>. However, Jones *et al.* could not confirm these findings<sup>13</sup>. To date, no IPD analyses have been performed to study interaction effects in frequently applied OA interventions. The primary aim of this study is to evaluate the efficacy of IA glucocorticoids for knee or hip OA in specific subgroups of patients according to the severity of pain and inflammatory signs, over both short- and long-term follow-up, using IPD from published trials.

## Methods

We carried out an IPD meta-analysis of RCTs studying the efficacy of IA glucocorticoid injections in patients with hip or knee OA. Full study protocol details have been published<sup>7</sup>.

### Study selection

The following inclusion criteria were applied for studies to be included in the OA Trial Bank for the current study purpose:

#### Type of studies

All RCTs, including crossover trials, evaluating one or more IA glucocorticoid preparations in patients with OA of the knee or hip. There were no language restrictions.

#### Participants

Participants have a diagnosis of OA of the knee or hip:

- (1) According to the American College of Rheumatology (ACR) classification criteria<sup>14,15</sup>.
- (2) On the basis of detailed clinical and/or radiographic information.

Studies including a subgroup of knee or hip OA patients were also included.

#### Types of interventions

All IA glucocorticoid preparations used for treatment of OA of the knee or hip in humans, compared to control treatments including: placebo, IA hyaluronan/hylan, other doses of IA glucocorticoids, usual conservative treatments, or compared to different types of injection procedures of glucocorticoids. Trials were grouped into three different comparisons: (1) IA glucocorticoid injection vs placebo; (2) IA glucocorticoid injection vs hyaluronic acids and (3) IA glucocorticoid injection vs tidal irrigation.

#### Types of baseline assessments

- (1) Important confounders: as a minimum baseline severity of pain, age and gender should have been assessed at baseline.
- (2) If available: Signs of inflammation should have been assessed at baseline, either by physical examination (warmth, effusion) or by additional testing (ultrasound, MRI, biopsy, serum CRP/ESR).

#### Types of outcomes

The minimum criterion for inclusion was reporting of pain. The primary outcome measure was pain severity at short-term (up to 4 weeks) follow-up. Secondary outcomes included pain severity at mid-term (closest to 3 months) and long-term follow-up (closest to 12 months). Information regarding other OMERACT III core set of outcome measures including physical function and patient global assessment were analysed when feasible<sup>16</sup>.

### Subgroup analyses

Subgroup analyses were performed for the primary and secondary outcomes in the subgroups of patients with and without severe pain ( $\geq 70$  on 0–100 scale) and with and without inflammatory signs (yes/no).

### Identification of eligible studies

The following databases were searched from 1995 (based on availability of data sets and authors) until 19 June 2012 for RCTs of IA glucocorticoid vs control treatment for OA of the knee or hip: the Cochrane Central Register of Controlled Trials (CENTRAL); MEDLINE (PubMed); EMBASE, Web of Science, Scopus, Cinahl, Pedro and the controlled trial registers (Appendix 1). In addition, reference lists were hand searched for further identification of published work. Potential on-going studies were searched by Horizon scanning documents from Arthritis Research UK (including European Patent Office; Intellectual Property Office; NHS – Database of Uncertainties about the Effects of Treatments (DUETS); ISRCTN Registry of Clinical Trials; [ClinicalTrials.gov](http://ClinicalTrials.gov); UKCRN Portfolio Database; Australian New Zealand Clinical Trials Registry; Netherlands Trials Register; German Clinical Trials Register).

Two review authors (MM, SB) independently selected citations based on titles and abstracts. Full articles were obtained for the citations that met the eligibility criteria and assessed by the two review authors independently. The OA Trial Bank board members were consulted if consensus was not reached.

### Data collection and transfer

All corresponding authors of eligible trials were approached and asked for their data following the OA Trial Bank protocol and terms<sup>7</sup>. All data-deliverers signed the data delivery license agreement. Data sets were accepted in any kind of format, provided that variables and categories were adequately labelled within the data set or with a separate codebook. The original data collection files were kept in their original version and saved on a secured server at the Erasmus MC University Medical Center in Rotterdam. To ensure quality, all data were checked for consistency and numbers were compared with published papers. In case of differences, authors were contacted and discrepancies were resolved.

### Risk of bias assessment

The methodological quality of the studies was assessed using the twelve criteria recommended by the Cochrane Collaboration and were evaluated independently by two researchers (Appendix 2). The criteria were scored as ‘yes’ (low risk of bias), ‘no’ (high risk of bias) or ‘unclear’. Any disagreements between the review authors were resolved by discussion, including input from the OA Trial Bank board members. A study with a low risk of bias was defined as fulfilling six or more of the criteria items.

### Data extraction

From the published papers, details on the interventions and comparator groups were obtained. Data obtained from the original databases included patient characteristics (age, gender, BMI), disease specific characteristics (ACR criteria, radiographic information, signs of inflammation, duration of complaint), study characteristics (types of interventions, doses) and outcome measures measurements (pain, function and global perceived recovery). All randomized patients with a database record were entered in the pooled

database and all individual trials were assigned an individual random trial number.

### Data analyses

The primary outcome was pain severity at short-term follow-up. If available we used the VAS pain measure, otherwise the WOMAC pain score was used, followed by other Likert scores but converted into a VAS 0–100 scale. Secondary outcomes included pain severity assessed at other follow-up durations (mid-term and long-term follow-up), physical functioning (standardized to 0–100 scale) and global assessment<sup>16</sup>.

The heterogeneity of trials was measured using  $I^2$  – the inconsistency among studies that cannot be explained by chance<sup>17</sup>. An additional analysis was performed as appropriate by excluding the trials causing heterogeneity in order to reach an  $I^2$  index of below 50.

Overall effects between the different comparative treatments on the primary outcome pain at all follow-up points were estimated using multilevel regression analyses. The analyses were adjusted for baseline pain, age and gender. Data were not imputed since all trials included had less than 15% of missing values.

The subgroup factors were, based on consensus, standardized to (1) severe pain, yes ( $\geq 70$  points) or no ( $< 70$  points) and (2) signs of inflammation (yes or no). In addition separate pooled analysis was undertaken for the different definitions of inflammation.

All analyses were repeated for hip and knee OA participants separately where more than one RCTs could be included in the analyses.

Multilevel regression analyses were applied to estimate the magnitude of the effects in the different subgroups with the individuals nested within each study, adjusted for age and gender. To assess potential subgroup effects, a random-effects linear regression model was used to calculate interaction effects. The model included the dependent variable, i.e., pain intensity at follow-up (0–100 scale) and independent variables, i.e., treatment (glucocorticoid injection or control), the effect modifier (severe pain (yes or no) or signs of inflammation (yes or no)), and an interaction term (pain BY treatment or inflammation BY treatment). The interaction effects represent the combined effects of severe pain or inflammation on pain severity and therefore represent the difference in effectiveness for the subgroup effects of IA glucocorticoid injection on pain severity. Interaction effects were only tested for these comparisons including more than one RCT. Interaction effect with  $P$ -value less than 0.05 was considered as statistically significant, indicating that the outcome depends on the severity of pain or signs of inflammation at baseline. For statistical significant interaction terms, separate subgroup effects were calculated to assist the interpretation of the results. The clinical significance of the interaction effect was estimated by the effect size (Cohen's  $d$  – the adjusted effect estimate of the interaction term divided by the pooled standard deviation of the baseline pain scores). An effect size of 0.2 was considered small and 0.5 moderate, while an effect size  $> 0.8$  indicates a large clinical effect<sup>18</sup>.

## Results

### Description of the studies

Of the 420 publications identified from the literature search, 43 publications met the eligibility criteria. Of these, 13 were duplicate publications and therefore 30 publications were eligible. A total of 23 authors were for several reasons unresponsive (Fig. 1)<sup>12,13,19–39</sup>. Following written request, authors of seven studies agreed to participate and were able to deliver their data to the OA Trial Bank.




Fig. 1. Flow diagram of search and included studies.

These seven published RCTs included 620 patients fulfilling the eligibility criteria and were included in the OA Trial Bank for the current study purpose<sup>40–46</sup>. Of these, four studies<sup>41,43,45,46</sup> compared glucocorticoids ( $n = 116$ ) with placebo ( $n = 107$ ), two studies<sup>41,44</sup> compared glucocorticoids ( $n = 72$ ) with hyaluronic acid ( $n = 71$ ), two studies<sup>40,46</sup> compared glucocorticoids ( $n = 104$ ) and tidal irrigation ( $n = 92$ ) and one study<sup>42</sup> compared glucocorticoids with botulinum toxin injections ( $n = 60$ ). An overview of the included studies is presented in Table I. Five studies<sup>40,42–44,46</sup> included patients with knee OA only and two<sup>41,45</sup> included hip OA patients only. All studies reported on pain at both short- and mid-term follow-up, while six studies reported on function outcomes (WOMAC) and three studies reported on a global assessment.

Table II presents the baseline characteristics of the study participants for each comparison. The average age was about 65 years and 49.7% were women. Severe pain was present in 34.4% of the total population, with the highest number in the studies comparing glucocorticosteroid injections with hyaluronic acids. Inflammatory signs, measured in five studies, were present in 41.8% of all subjects.

The risk of bias scores of the individual studies are presented in Table III. All studies scored positive on at least five out of 11 points, with all studies scoring positive on the items ‘method of

randomization’, ‘compliance acceptable’ and ‘timing of outcome assessment’. Two studies scored negative on all three blinding issues<sup>40,41</sup>.

#### Overall treatment effects

A significant overall effect on the primary outcome pain severity at short-term follow-up was seen of IA glucocorticoid injection compared to placebo (Mean Difference (MD) 18.72 (95% Confidence Interval (CI) 13.04–24.41)) and compared to hyaluronic acid (MD 9.38 (95% CI 5.69–13.09)) (Table IV).

At long-term follow-up there was a significant overall negative effect of IA glucocorticosteroid injection compared to tidal irrigation (MD  $-4.57$  (95% CI  $-7.40$  to  $-1.74$ )).

At mid-term a significant overall positive effect of glucocorticoid injection was found compared to placebo (MD 10.00 (95% CI 3.88–16.13)) but no statistical significant differences were found at long-term following when glucocorticoid injection was compared to placebo.

Subgroup analyses among knee and hip OA patients separately revealed overall significant effects of IA glucocorticoid injection compared to placebo at short-term in both patient populations;

**Table I**  
Characteristics of trials included in OA Trial Bank for IA glucocorticosteroid injections

	N at baseline	Type of OA	Glucocorticosteroid intervention	Control interventions	Outcomes	Inflammation	Follow-up
Arden <i>et al.</i> (2008) <sup>40</sup>	150	Knee	40 mg triamcinolone acetonide and 2 ml lignocaine (n = 79)	1 Tidal irrigation (n = 71)	- Pain (VAS) - WOMAC pain - WOMAC physical functioning - WOMAC stiffness - WOMAC total - Global assessment (5 pt Likert)	Presence of effusion by physical examination (small/moderate/large)	2, 4, 12 and 26 weeks
Atchia <i>et al.</i> (2011) <sup>41</sup>	77	Hip	Methylprednisolone acetate (depomedrone) 3 ml/120 mg (n = 19)	1 Placebo (3 mg saline) (n = 19) 2 Standard care (n = 20) 3 Hyaluronic acid (durolane) 3 ml/60 mg (n = 19)	- Pain, worst (NRS) - WOMAC pain - WOMAC physical functioning - WOMAC stiffness	Presence of synovitis >7 mm on ultrasound	1, 4, 8 and 16 weeks
Boon <i>et al.</i> (2010) <sup>42</sup>	60	Knee	Methylprednisolone acetate 40 mg (n = 20)	1 Low dose botulinum toxin type A (100 units) (n = 20) 2 High dose botulinum toxin type A (200 units) (n = 20)	- Pain (VAS) - WOMAC pain - WOMAC physical functioning - WOMAC stiffness - WOMAC total	Presence of effusion by physical examination (mild/moderate/large)	8, 12 and 26 weeks
Chao <i>et al.</i> (2010) <sup>43</sup>	79	Knee	40 mg triamcinolone acetonide (n = 40)	Placebo (1 cc 0.9% saline) (n = 39)	- Pain (VAS) - WOMAC pain - WOMAC total	Pathologic effusion of ≥5 mm present on ultrasound	4 and 12 weeks
de Campos <i>et al.</i> (2013) <sup>44</sup>	104	Knee	20 mg triamcinolone hexacetonide + 6 ml hylan GF20 (n = 52)	Hylan GF20 (6 ml) (n = 52)	- Pain (VAS) - WOMAC pain - WOMAC total - WOMAC physical functioning - WOMAC stiffness - Global assessment	—	1, 4, 12 and 24 weeks
Lambert <i>et al.</i> (2007) <sup>45</sup>	52	Hip	10 mg bupivacaine, 40 mg triamcinolone (n = 31)	Placebo (10 mg bupivacaine, 2 ml saline) (n = 21)	- Pain (VAS) - WOMAC physical functioning - WOMAC stiffness - Global assessment	—	1, 2, 3 and 6 months
Ravaud <i>et al.</i> (1999) <sup>46</sup>	98	Knee	3.75 mg cortivazol in 1.5 ml (n = 25)	1 Placebo (1.5 ml 0.9% saline) (n = 28) 2 Joint lavage and IA placebo (n = 21) 3 Joint lavage and IA corticosteroid (n = 24)	- Pain (VAS) - Global status (VAS)	Evidence of effusion by clinical assessment (present or not)	1, 4, 12 and 24 weeks

13.93 (95% CI 6.41–21.46) and 24.54 (95% CI 16.28–32.82), respectively. At mid-term, a significant overall effect was seen of IA glucocorticoid injection compared to placebo in hip OA patients only (13.58 (95% CI 3.53–23.62)) but not in knee OA patients (6.90 (95% CI –0.66 to 14.47)). No significant treatment effects were found at long-term follow-up in either the knee or hip OA subgroups (data not shown).

#### Baseline pain severity and treatment effect

A significant positive interaction (13.91; 95% CI 1.50–26.31) was found between severe pain at baseline and the treatment effect of IA glucocorticoid injection compared to placebo at short-term follow-up (Table V). This was illustrated by the statistically significantly larger reduction in short-term pain (adjusted effect estimate 28.54; 95% CI 13.56–43.51) in patients with severe pain compared

to those with less severe pain at baseline (14.97; 95% CI 9.57–20.37) when receiving IA glucocorticoid injection compared to placebo. No significant interaction effects were found between severe pain and the treatment effect of IA glucocorticoid injection compared to placebo at mid- and long-term follow-up. No significant interaction effects were found between severe pain and the treatment effect of IA glucocorticoid injection compared to hyaluronic acid and tidal irrigation.

Subgroup analysis on knee OA patients also revealed a significant interaction (18.04; 95% CI 1.87–34.20) between severe pain and IA glucocorticoid injection compared to placebo at short-term follow-up. This was illustrated by the statistically significantly larger reduction in short-term pain (adjusted effect estimate 27.28; 95% CI 6.72–47.83) in patients with severe pain compared to those with less severe pain at baseline (9.54; 95% CI 2.65–16.44) when receiving IA glucocorticoid injection compared to placebo. No



**Table II**

Baseline characteristics of patients in the study, means (SD) (unless otherwise stated)

	Total population, N = 620	Comparison 1: glucocorticosteroid vs placebo, N = 222	Comparison 2: glucocorticosteroid vs hyaluronic acids, N = 142	Comparison 3: glucocorticosteroid vs joint lavage, N = 196
Age (years)	64.74 (10.47)	64.47 (11.23)	64.15 (10.24)	66.28 (9.56)
Gender, % female	308 (49.7%)	91 (41%)	99 (69.7%)	82 (41.8%)
BMI (kg/m <sup>2</sup> )	29.82 (5.06)*	28.44 (4.89)§	29.16 (4.73)	30.80 (5.09)
Hip OA, %	129 (20.8%)	90 (40.5%)	38 (26.8%)	—
Knee OA, %	491 (79.2%)	132 (59.5%)	104 (73.2%)	196 (100%)
KL grade, %				
1	35 (5.6%)	10 (4.5%)	20 (14.1%)	4 (2.0%)
2	205 (33.1%)	41 (18.5%)	41 (28.9%)	107 (54.6%)
3	202 (32.6%)	66 (29.7%)	55 (38.7%)	39 (19.9%)
4	71 (11.5%)	25 (11.3%)	25 (17.6%)	20 (10.2%)
Missing	107 (17.3%)	80 (64.0%)	1 (0.7%)	26 (13.3%)
Duration of complaints (months)	76.98 (102.57)†	86.19 (122.62)	40.64 (36.02)**	69.36 (87.22)
Inflammation, %	259 (41.8%)‡	88 (39.6%)¶	28 (19.7%)#	110 (56.1%)
Severe pain (≥70 points), %	213 (34.4%)	61 (27.5%)	60 (42.3%)	65 (33.2%)
Pain (0–100)	59.92 (20.34)	58.63 (17.58)	64.50 (21.21)	57.71 (23.02)††

\* N = 485.

† N = 495.

‡ N = 458.

§ N = 91 (not available for Lambert and Chao).

|| Not available for Chao.

¶ N = 165 (not available for Lambert).

# N = 38 (not available for de Campos).

\*\* N = 36 (not available for de Campos).

†† N = 187.

significant interaction was found at mid-term follow-up (5.15; 95% CI –11.79 to 22.10). No significant interaction effects between severe pain and IA glucocorticoid injection compared to placebo were found in hip OA patients at any follow-up point (data not shown).

#### Baseline inflammatory signs and treatment effect

No significant interaction effects were found between inflammatory signs and IA glucocorticoid injections compared to placebo and compared to tidal irrigation at all follow-up points (Table VI).

The interaction effect between inflammatory signs detected by ultrasound and IA glucocorticoid injection compared to placebo at short-term follow-up was not statistically significant (9.04; 95% CI –0.71 to 18.80) (Table VII).

No significant interaction effects were found between inflammatory signs and IA glucocorticoid injection and placebo in knee OA patients on both short-term (–3.83; 95% CI –18.98 to 11.31) and mid-term (1.49; 95% CI –13.96 to 16.94) follow-up. No analyses could be performed on hip OA patients only, since only one study was available.

**Table III**

Risk of bias assessment

	A1	B2	C3	C4	C5	D6	D7	E8	E9	E10	E11
Arden <i>et al.</i> (2008) <sup>40</sup>	+	?	–	–	–	+	?	–	+	+	+
Atchia <i>et al.</i> (2011) <sup>41</sup>	+	?	–	–	–	+	+	–	?	+	+
Boon <i>et al.</i> (2010) <sup>42</sup>	+	?	+	?	+	–	?	–	+	+	+
Chao <i>et al.</i> (2010) <sup>43</sup>	+	?	+	?	+	–	?	+	?	+	+
de Campos <i>et al.</i> (2013) <sup>44</sup>	+	?	+	?	+	+	?	+	?	+	+
Lambert <i>et al.</i> (2007) <sup>45</sup>	+	+	+	+	+	+	+	–	+	+	+
Ravard <i>et al.</i> (1999) <sup>46</sup>	+	?	+	+	+	+	+	+	+	+	+

A1. Method of randomization adequate; B2. Treatment allocation concealed; C3. Patient blinded to the intervention; C4. Care provider blinded to the intervention; C5. Outcome assessor blinded to the intervention; D6. Drop-out rate described and acceptable; D7. Randomized participants analysed in the group to which they were allocated; E8. Groups similar at baseline regarding the most important prognostic indicators; E9. Co-interventions avoided or similar; E10. Compliance acceptable; E11. Timing of the outcome assessment similar in all groups.

## Discussion

The IPD meta-analyses on IA glucocorticoid injection showed that there is an overall positive, and clinically relevant (>10 points on 0–100 scale), effect of IA glucocorticoid injection compared to placebo at short- and mid-term follow-up, with estimate reduction in pain of 18.7 and 10.0 (on a 0–100 scale) respectively. Compared to hyaluronic acid injection, an overall positive effect of IA glucocorticoid injection was found at short-term only. Patients with severe baseline pain had a significantly larger reduction in short-term pain (adjusted effect estimate 28.54; 95% CI 13.56–43.51) than those with less severe pain at baseline (14.97; 95% CI 9.57–20.37) when receiving IA glucocorticoid injection compared to placebo. The difference was well presented with the interaction term between the treatment and the subgroup indicator in the multilevel regression model (Table V). Similar result was observed in knee OA with a slightly greater difference between severe vs less severe knee pain at baseline (18.04; 95% CI 1.87–34.20). However, no firm conclusions could be drawn on the subgroup effect of inflammation, though a positive non-significant trend was noted for the effectiveness of IA glucocorticoid injection in the subgroup of patients with inflammatory signs measured by ultrasound. No statistically significant interaction effects were found in the subgroup of hip OA patients.

IA glucocorticosteroid injections are commonly applied to relieve symptoms of knee and hip OA; however, factors predicting the response to treatment are poorly understood. Maricar *et al.* aimed to determine factors associated with response to IA glucocorticosteroid injection by summarizing the literature<sup>47</sup>. The authors of this review concluded that no consistent predictors of response were identified for IA glucocorticosteroid injection in knee OA. However, effusion, absence of synovitis, delivering injections under US guidance, structural severity of disease and pain were features that were reported by individual studies as enhancing the response of IA glucocorticosteroid injections<sup>12,13,40,43,48</sup>.

The current meta-analysis aimed to identify the possible subgroup effects of severe pain and inflammatory signs. In agreement

**Table IV**

Overall effectiveness on primary outcome pain severity (0–100 scale)

	N total	N intervention group	N control group	Effect estimate (95% CI)	Adjusted effect estimate* (95% CI)	I <sup>2</sup>	P-value
<b>IA glucocorticosteroid versus placebo (N = 222)</b>							
Short-term (four trials) <sup>41,43,45,46</sup>	207	107	100	17.74 (11.65; 23.82)	18.72 (13.04; 24.41)	67%	<b>&lt;0.001</b>
Mid-term (four trials) <sup>41,43,45,46</sup>	181	98	83	7.99 (1.44; 14.53)	10.00 (3.88; 16.13)	67%	<b>0.002</b>
Long-term (two trials) <sup>45,46</sup>	71	42	29	6.54 (−6.94; 20.02)	6.25 (−8.59; 21.10)	0%	0.403
<b>IA glucocorticosteroid versus hyaluronic acid (N = 142)</b>							
Short-term (two trials) <sup>41,44</sup>	142	71	71	9.06 (5.05; 13.08)	9.38 (5.69; 13.09)	0%	<b>&lt;0.001</b>
Mid-term (two trials) <sup>41,44</sup>	131	66	65	0.66 (−3.46; 4.77)	0.97 (−2.96; 4.90)	0%	0.627
Long-term (one trial) <sup>44</sup>	93	47	46	−0.38 (−5.01; 4.25)	0.22 (−4.30; 4.75)	n.a.	0.921
<b>IA glucocorticosteroid versus tidal irrigation (N = 196)</b>							
Short-term (two trials) <sup>40,46</sup>	191	102	89	0.83 (−1.63; 3.30)	1.08 (−1.31; 3.47)	51%	0.374
Mid-term (two trials) <sup>40,46</sup>	179	93	86	−1.60 (−4.36; 1.16)	−1.21 (−3.83; 1.41)	51%	0.363
Long-term (two trials) <sup>40,46</sup>	172	90	82	−4.85 (−7.68; −2.02)	−4.57 (−7.40; −1.74)	51%	<b>0.02</b>

\* Adjusted for baseline pain, age and gender; statistical significant differences ( $P < 0.05$ ) in bold; n.a. not applicable.**Table V**Interaction effects of severe pain ( $\geq 70$  points) with IA glucocorticoid injection for primary outcome pain severity (0–100 scale)

	Severe pain n/N glucocorticosteroid group	Severe pain n/N control group	Unadjusted interaction effect estimate (95% CI)	Adjusted interaction effect estimate* (95% CI)	Effect size	Adjusted P-value for interaction term
<b>IA glucocorticosteroid injection vs placebo (four trials)</b>						
Short-term pain <sup>41,43,45,46</sup>	28/107	30/100	14.93 (2.24; 27.63)	13.91 (1.50; 26.31)	<b>0.56</b>	<b>0.028</b>
Mid-term pain <sup>41,43,45,46</sup>	26/98	19/83	3.01 (−10.66; 16.87)	1.84 (−11.27; 14.94)	0.07	0.782
Long-term pain <sup>45,46</sup>	15/42	11/29	−4.23 (−32.56; 24.09)	−4.31 (−33.73; 25.11)	−0.17	0.771
<b>IA glucocorticosteroid injection vs hyaluronic acid (two trials)</b>						
Short-term pain <sup>41,44</sup>	33/71	27/71	0.85 (−7.05; 8.76)	3.11 (−4.36; 10.59)	0.10	0.412
Mid-term pain <sup>41,44</sup>	31/47	25/65	−4.68 (−12.82; 3.45)	−3.15 (−11.14; 4.85)	−0.10	0.438
<b>IA glucocorticosteroid injection vs tidal irrigation (two trials)</b>						
Short-term pain <sup>40,46</sup>	32/96	33/87	1.85 (−3.19; 6.90)	1.28 (−3.68; 6.24)	0.04	0.610
Mid-term pain <sup>40,46</sup>	29/88	28/83	0.30 (−5.44; 6.05)	−0.28 (−5.77; 5.21)	−0.01	0.919
Long-term pain <sup>40,46</sup>	28/85	27/79	4.12 (−1.82; 10.06)	3.42 (−2.44; 9.29)	0.10	0.251

statistical significant differences ( $p < 0.05$ ) in bold.

\* Adjusted for age and gender and baseline pain.

**Table VI**

Interaction effects of inflammation with IA glucocorticoid injection for primary outcome pain severity (0–100 scale)

	Inflammation n/N intervention group	Inflammation n/N control group	Unadjusted interaction effect estimate (95% CI)	Adjusted interaction effect estimate* (95% CI)	Effect size	Adjusted P-value for interaction term
<b>IA glucocorticosteroid vs placebo (three trials)</b>						
Short-term pain <sup>41,43,46</sup>	39/77	43/79	2.14 (−11.36; 15.65)	7.34 (−4.97; 19.65)	0.29	0.24
Mid-term pain <sup>41,43,46</sup>	39/71	34/66	3.76 (−10.52; 18.04)	11.08 (−1.34; 23.50)	0.44	0.08
<b>IA glucocorticosteroid vs tidal irrigation (two trials)</b>						
Short-term pain <sup>40,46</sup>	60/102	47/89	1.29 (−3.68; 6.25)	0.73 (−4.07; 5.53)	0.02	0.765
Mid-term pain <sup>40,46</sup>	58/93	46/86	1.68 (−3.94; 7.30)	1.77 (−3.47; 7.01)	0.05	0.505
Long-term pain <sup>40,46</sup>	57/90	43/82	4.25 (−1.50; 10.00)	5.24 (−0.35; 10.84)	0.16	0.066

\* Adjusted for age and gender and baseline pain.

**Table VII**

Interaction effects of inflammation measured by ultrasound with IA glucocorticoid injection for primary outcome pain severity (0–100 scale)

	Total N	Inflammation n/N intervention group	Inflammation n/N control group	Unadjusted interaction effect estimate (95% CI)	Adjusted interaction effect estimate* (95% CI)	Effect size	Adjusted P-value for interaction term
<b>IA glucocorticosteroid vs placebo (two trials)</b>							
Short-term pain <sup>41,43</sup>	103	29/52	27/51	9.22 (−5.21; 23.64)	9.04 (−0.71; 18.80) <sup>†</sup>	0.39	0.069
Mid-term pain <sup>41,43</sup>	96	29/49	25/47	6.53 (−9.18; 22.24)	7.14 (−4.27; 18.55) <sup>‡</sup>	0.31	0.217

\* Adjusted for age and gender and baseline pain.

<sup>†</sup> Baseline pain: 0.84 (0.69; 0.99),  $P < 0.001$ .<sup>‡</sup> Baseline pain: 0.82 (0.65; 0.99),  $P < 0.001$ .

with Maricar *et al.*<sup>47</sup> we found a significant and clinically relevant interaction effect (moderate effect with effect size 0.56) between severe pain at baseline and IA glucocorticosteroid injection. Severe pain was defined as a pain score higher than 70 points on a 0–100 scale. Earlier studies have indicated that radiographic severity of

knee OA would be predictive to response on IA glucocorticosteroid injection<sup>40,49</sup> while self-perceived symptom severity was not found predictive for the treatment response in two other studies<sup>12,50</sup>. The fact that different outcomes are seen between these studies and our meta-analyses could be due to the small sample size of the

individual studies and the difference in studies included. Following our protocol, we analysed the subgroup effect of patients with severe pain on an easy applicable measure for clinical practice. The results of this meta-analysis indicate that both patients with and without severe pain at baseline clinically benefit from IA glucocorticosteroid injection compared to placebo at short-term follow-up. Although patients with severe pain achieved significantly more benefit from IA glucocorticosteroid injection compared with patients with less severe pain, with a clinically relevant difference of 14 points on a 0–100 pain scale. This effect seems to be most predominant in knee OA patients since no significant interaction effects were found in the small hip OA patient subgroup. However, no statistical significant subgroup effects were found on any of the other follow-up points or between the other comparisons. This is however consistent to the overall effect of IA glucocorticosteroid injection, primarily showing significant effects at short-term follow-up, with the largest, and clinically relevant, effect found at short-term follow-up, comparing IA glucocorticosteroid injection to placebo.

OA is sometimes considered a non-inflammatory degenerative disease, however it is now recognized that inflammation may play a role in the pathogenesis in at least some patients. IA glucocorticosteroid injections have been used for the treatment of OA for many years and it has been suggested that these injections are most effective in patients with evidence of inflammation on physical examination. The main indication for IA glucocorticoid use is to provide pain relief in patients whose condition remains unresponsive to or intolerant of oral systemic medication<sup>45</sup>. However, conflicting effects have been found in the different subgroups and most individual studies were underpowered to examine subgroup effects in OA populations<sup>12,43</sup>. In our pooled IPD meta-analysis a non-significant positive interaction was found for the short- and mid-term treatment response on IA glucocorticosteroid injection compared to placebo for patients with inflammatory signs, detected by ultrasound. However, by removing baseline pain from the adjusted analyses, the positive interaction between the ultrasound inflammation and the treatment was no longer seen. Therefore it seems that severe pain is the best and most easy measure to predict the treatment response of IA glucocorticosteroid injections of patients with knee or hip OA.

#### Strengths and limitations

The key strength of this study is that we used IPD from seven trials giving the study greater power than any of the individual studies that have been conducted on potential predictors of response for the treatment of IA glucocorticoid injection in patients with knee or hip OA. There was some heterogeneity within the first comparison (see Table IV). Therefore we repeated the analyses for both short- and mid-term subgroup effects of IA glucocorticoid injections compared to placebo by excluding the study of Chao *et al.* (reduction of  $I^2$  to 0%). This did however result in comparable effect estimates. In addition, all analyses performed were predefined and described in our published protocol<sup>7</sup>. There are also several limitations. Based on the literature we approached the authors of 43 potential eligible publications, including 13 duplicate publications. Of the 30 potentially available studies only seven authors agreed to participate. As a consequence, only two studies could be included for the analyses comparing IA glucocorticoid injection with hyaluronic acid and tidal irrigation and a possible selection bias might have occurred. This proves the challenge of collecting data of performed RCTs. Authors of nine publications indicated that the data were no longer available and data rights of an additional three RCTs were sold. This strengthens the rationale for the recent initiative of

journals to require authors to make trial data accessible on reasonable request.

We included the study of Boon *et al.* which was not included in the subgroup analyses since this was the only study comparing IA glucocorticoids with botulinum toxin. Since our intention was to include all studies with non-surgical comparators, we decided to include this study in the OA Trial Bank despite that this intervention was not pre-specified in our protocol paper.

We planned to perform subgroup analyses on both severe pain and signs of inflammation, however only four of the six studies included in the analyses actually measured signs of inflammation. As a consequence, the subgroup effect of inflammation could not be calculated for the comparison between IA glucocorticoid injection and hyaluronic acids and long-term analysis was only possible for the comparison between IA glucocorticoid injection and tidal irrigation. In addition, the subgroup analyses for inflammation are likely to be underpowered due to the low number of subjects included. Since inflammation was measured and reported in many different ways, it is therefore recommended that special interest groups will reach consensus on these measures to allow meta-analyses in future.

Finally, we were forced to make some amendments on our published protocol<sup>7</sup>. We intended to adjust for at least age, gender and BMI. However, since not all studies collected data to calculate the BMI, we were not able to adjust the analyses for BMI.

#### Clinical implications

This IPD meta-analysis shows that patients with severe pain at baseline significantly more benefit from IA glucocorticoid injection than those with less severe pain at short-term follow-up. However, both patients with and without severe pain show clinical relevant effects (>10 points on 0–100 pain scale) of IA glucocorticoids at short-term follow-up. No firm conclusions can be drawn on the additional benefit of IA glucocorticoid in the subgroup of patients with inflammatory signs due to the limited power of the study for this subgroup. Since severe pain is easy to measure in patients in daily practice, we suggest to use this measure to identify those patients with knee or hip OA who would benefit the most from IA glucocorticoid injections.

#### Author contributions

MvM, KD, MD, WZ, JWB, TM, SLSL, and SMAB-Z were involved in the study design and contributed to the interpretation of the results. MvM contacted the potential data-deliverers, coordinated the data collection, and performed the data analyses. NA, IA, FB, JC, RL and PR provided the data and were responsible for the data collection and individual study-designs. MvM wrote the manuscript together with KD, MD, WZ, JWB, TM, SLSL, SMAB-Z, NA, IA, FB, JC, RL and PR. MvM and SMAB-Z have full access to the study data. All authors approved the final manuscript.

#### Conflict of interest

The authors declare that they have no competing interests.

#### Role of funding source

Dutch Arthritis Foundation.

#### Acknowledgements

KD is part funded by the National Institute for Health Research (NIHR) Collaborations for Leadership in Applied Research and Care West Midlands and by a Knowledge Mobilisation Research Fellowship from the NIHR.



## Supplementary data

Supplementary data related to this article can be found at <http://dx.doi.org/10.1016/j.joca.2016.01.983>.

## References

1. National Collaborating Centre for Chronic C. 2008.
2. Zhang W, Doherty M, Arden N, Bannwarth B, Bijlsma J, Gunther KP, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCIIT). *Ann Rheum Dis* 2005;64:669–81.
3. Bierma-Zeinstra SM, Verhagen AP. Osteoarthritis subpopulations and implications for clinical trial design. *Arthritis Res Ther* 2011;13:213.
4. Brookes ST, Whitley E, Egger M, Smith GD, Mulheran PA, Peters TJ. Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test. *J Clin Epidemiol* 2004;57:229–36.
5. Brookes ST, Whitley E, Peters TJ, Mulheran PA, Egger M, Davey Smith G. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. *Health Technol Assess* 2001;5:1–56.
6. Groenwold RH, Donders AR, van der Heijden GJ, Hoes AW, Rovers MM. Confounding of subgroup analyses in randomized data. *Arch Intern Med* 2009;169:1532–4.
7. van Middelkoop M, Dziedzic KS, Doherty M, Zhang W, Bijlsma JW, McAlindon TE, et al. Individual patient data meta-analysis of trials investigating the effectiveness of intra-articular glucocorticoid injections in patients with knee or hip osteoarthritis: an OA Trial Bank protocol for a systematic review. *Syst Rev* 2013;2:54.
8. Zhang W, Nuki G, Moskowitz RW, Abramson S, Altman RD, Arden NK, et al. OARS recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. *Osteoarthritis Cartilage* 2010;18:476–99.
9. Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. *Arthritis Care Res (Hoboken)* 2012;64:465–74.
10. Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G. Intraarticular corticosteroid for treatment of osteoarthritis of the knee. *Cochrane Database Syst Rev* 2006;CD005328.
11. Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, et al. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCIIT). *Ann Rheum Dis* 2003;62:1145–55.
12. Gaffney K, Ledingham J, Perry JD. Intra-articular triamcinolone hexacetonide in knee osteoarthritis: factors influencing the clinical response. *Ann Rheum Dis* 1995;54:379–81.
13. Jones A, Doherty M. Intra-articular corticosteroids are effective in osteoarthritis but there are no clinical predictors of response. *Ann Rheum Dis* 1996;55:829–32.
14. Altman R, Alarcon G, Appelrouth D, Bloch D, Borenstein D, Brandt K, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. *Arthritis Rheum* 1991;34:505–14.
15. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. *Arthritis Rheum* 1986;29:1039–49.
16. Bellamy N, Kirwan J, Boers M, Brooks P, Strand V, Tugwell P, et al. Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III. *J Rheumatol* 1997;24:799–802.
17. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003;327:557–60.
18. Cohen J. *Statistical Power Analysis for the Behavioral Sciences*. 2nd edn. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.
19. Bankhurst AD, Nunez SE, Draeger HT, Kettwich SC, Kettwich LG, Sibbitt Jr WL. A randomized controlled trial of the reciprocating procedure device for intraarticular injection of corticosteroid. *J Rheumatol* 2007;34:187–92.
20. Caborn D, Rush J, Lanzer W, Parenti D, Murray C, Synvisc 901 Study G. A randomized, single-blind comparison of the efficacy and tolerability of hylan G-F 20 and triamcinolone hexacetonide in patients with osteoarthritis of the knee. *J Rheumatol* 2004;31:333–43.
21. Kullenberg B, Runesson R, Tuvhag R, Olsson C, Resch S. Intra-articular corticosteroid injection: pain relief in osteoarthritis of the hip? *J Rheumatol* 2004;31:2265–8.
22. Leopold SS, Redd BB, Warne WJ, Wehrle PA, Pettis PD, Shott S. Corticosteroid compared with hyaluronic acid injections for the treatment of osteoarthritis of the knee. A prospective, randomized trial. *J Bone Joint Surg Am* 2003;85-A:1197–203.
23. Ozturk C, Atamaz F, Hepguler S, Argin M, Arkun R. The safety and efficacy of intraarticular hyaluronan with/without corticosteroid in knee osteoarthritis: 1-year, single-blind, randomized study. *Rheumatol Int* 2006;26:314–9.
24. Pyne D, Ioannou Y, Mootoo R, Bhanji A. Intra-articular steroids in knee osteoarthritis: a comparative study of triamcinolone hexacetonide and methylprednisolone acetate. *Clin Rheumatol* 2004;23:116–20.
25. Qvistgaard E, Christensen R, Torp-Pedersen S, Bliddal H. Intra-articular treatment of hip osteoarthritis: a randomized trial of hyaluronic acid, corticosteroid, and isotonic saline. *Osteoarthritis Cartilage* 2006;14:163–70.
26. Samborski W, Stratz T, Mackiewicz S, Muller W. Intra-articular treatment of arthritides and activated osteoarthritis with the 5-HT<sub>3</sub> receptor antagonist tropisetron. A double-blind study compared with methylprednisolone. *Scand J Rheumatol Suppl* 2004;119:51–4.
27. Shimizu M, Higuchi H, Takagishi K, Shinozaki T, Kobayashi T. Clinical and biochemical characteristics after intra-articular injection for the treatment of osteoarthritis of the knee: prospective randomized study of sodium hyaluronate and corticosteroid. *J Orthop Sci* 2010;15:51–6.
28. Skwara A, Peterlein CD, Tibesku CO, Rosenbaum D, Fuchs-Winkelmann S. Changes of gait patterns and muscle activity after intraarticular treatment of patients with osteoarthritis of the knee: a prospective, randomised, doubleblind study. *Knee* 2009;16:466–72.
29. Spitzer AI, Bockow BI, Brander VA, Yates JW, Maccarter DK, Gudger GK, et al. Hylan G-F 20 improves hip osteoarthritis: a prospective, randomized study. *Phys Sportsmed* 2010;38:35–47.
30. Stein A, Helmke K, Szopko C, Stein C, Yassouridis A. Intra-artikuläre Morphin- versus Steroidapplikation bei Gonarthrose und Arthritis im akut schmerzhaften Gelenk. [Intra-articular

- morphine versus steroid administration to the acutely painful joint in gonarthrosis and arthritis]. *Dtsch Med Wochenschr* 1996;121:255.
31. Yavuz U, Sokucu S, Albayrak A, Ozturk K. Efficacy comparisons of the intraarticular steroidal agents in the patients with knee osteoarthritis. *Rheumatol Int* 2012;32:3391–6.
  32. Young L, Katrib A, Cuello C, Vollmer-Conna U, Bertouch JV, Roberts-Thomson PJ, *et al.* Effects of intraarticular glucocorticoids on macrophage infiltration and mediators of joint damage in osteoarthritis synovial membranes: findings in a double-blind, placebo-controlled study. *Arthritis Rheum* 2001;44:343–50.
  33. Baratham A, Lukert BP, Lindsley HB, Herbert B. Effects of intraarticular (IA) corticosteroid injections on bone markers and endogenous cortisol in patients with knee osteoarthritis (OA), a pilot study. *Arthritis Rheum* 2010;62:943.
  34. Beyaz SG, Arun O, Tufek A, Tokgoz O, Karaman H. Comparison of efficacy of intraarticularly applied morphine and steroid in patients with knee osteoarthritis. *Reg Anesth Pain Med* 2011;36:E180.
  35. Bias P, Labrenz R, Rose P. Sustained-release dexamethasone palmitate: pharmacokinetics and efficacy in patients with activated inflammatory osteoarthritis of the knee. *Clin Drug Investig* 2001;21:429–36.
  36. Ellis ME, Lun VMY, Preston Wiley J. Combination treatment for knee osteoarthritis. *Clin J Sport Med* 2011;21:374–5.
  37. Folman Y, Shabat S. Local treatment of a painful knee with corticosteroids: the efficacy of intra-articular injection compared with peri-articular soft tissue infiltration. *J Musculoskelet Pain* 2011;19:154–7.
  38. Frizziero L, Ronchetti IP. Intra-articular treatment of osteoarthritis of the knee: an arthroscopic and clinical comparison between sodium hyaluronate (500–730 kDa) and methylprednisolone acetate. *J Orthop Traumatol* 2002;3:89–96.
  39. Reshetov PP, Tverdokhleba Iu P, Bezmenov VA. Primenenie gidrokortizona v sochetanii s ul'trazvukom u bol'nykh gonartrozom. [The use of hydrocortisone combined with ultrasound with gonarthrosis patients]. *Vopr Kurortol Fizioter Lech Fiz Kult* 2000;4:47–8.
  40. Arden NK, Reading IC, Jordan KM, Thomas L, Platten H, Hassan A, *et al.* A randomised controlled trial of tidal irrigation vs corticosteroid injection in knee osteoarthritis: the KIVIS Study. *Osteoarthritis Cartilage* 2008;16:733–9.
  41. Atchia I, Kane D, Reed MR, Isaacs JD, Birrell F. Efficacy of a single ultrasound-guided injection for the treatment of hip osteoarthritis. *Ann Rheum Dis* 2011;70:110–6.
  42. Boon AJ, Smith J, Dahm DL, Sorenson EJ, Larson DR, Fitz-Gibbon PD, *et al.* Efficacy of intra-articular botulinum toxin type A in painful knee osteoarthritis: a pilot study. *PM R* 2010;2:268–76.
  43. Chao J, Wu C, Sun B, Hose MK, Quan A, Hughes TH, *et al.* Inflammatory characteristics on ultrasound predict poorer longterm response to intraarticular corticosteroid injections in knee osteoarthritis. *J Rheumatol* 2010;37:650–5.
  44. de Campos GC, Rezende MU, Pailo AF, Frucchi R, Camargo OP. Adding triamcinolone improves viscosupplementation: a randomized clinical trial. *Clin Orthop Relat Res* 2013;471:613–20.
  45. Lambert RG, Hutchings EJ, Grace MG, Jhangri GS, Conner-Spady B, Maksymowych WP. Steroid injection for osteoarthritis of the hip: a randomized, double-blind, placebo-controlled trial. *Arthritis Rheum* 2007;56:2278–87.
  46. Ravaut P, Moulinier L, Giraudeau B, Ayral X, Guerin C, Noel E, *et al.* Effects of joint lavage and steroid injection in patients with osteoarthritis of the knee: results of a multicenter, randomized, controlled trial. *Arthritis Rheum* 1999;42:475–82.
  47. Maricar N, Callaghan MJ, Felson DT, O'Neill TW. Predictors of response to intra-articular steroid injections in knee osteoarthritis – a systematic review. *Rheumatology (Oxford)* 2013;52:1022–32.
  48. Sibbitt Jr WL, Band PA, Kettwich LG, Chavez-Chiang NR, Delea SL, Bankhurst AD. A randomized controlled trial evaluating the cost-effectiveness of sonographic guidance for intra-articular injection of the osteoarthritic knee. *J Clin Rheumatol* 2011;17:409–15.
  49. Smith MD, Wetherall M, Darby T, Esterman A, Slavotinek J, Roberts-Thomson P, *et al.* A randomized placebo-controlled trial of arthroscopic lavage versus lavage plus intra-articular corticosteroids in the management of symptomatic osteoarthritis of the knee. *Rheumatology (Oxford)* 2003;42:1477–85.
  50. Dieppe PA, Sathapatayavongs B, Jones HE, Bacon PA, Ring EF. Intra-articular steroids in osteoarthritis. *Rheumatol Rehabil* 1980;19:212–7.